Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $125,000.00 in Stock

Key Points

• Director Robert Hershberg sold 25,000 Recursion Pharmaceuticals shares at $5.00 each, totaling $125,000. The transaction occurred under a pre-arranged Rule 10b5-1 plan and reduced his holdings by 13.36% to 162,156 shares.
• RXRX shares fell 7.8% to $4.27 during Wednesday trading, with volume more than twice its average. The company has a $2.29 billion market capitalization and trades at a negative P/E ratio.
• Recursion’s latest quarterly results missed expectations, with a $0.25 per-share loss and $7.67 million in revenue versus estimates of $0.24 and $10.97 million, respectively. Analysts have an overall “Hold” rating and an average price target of $8.06.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Robert Hershberg sold 25,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total value of $125,000.00. Following the transaction, the director owned 162,156 shares in the company, valued at approximately $810,780. This represents a 13.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Recursion Pharmaceuticals Trading Down 7.8%

Shares of Recursion Pharmaceuticals stock traded down $0.36 during trading hours on Wednesday, hitting $4.27. The company's stock had a trading volume of 40,600,630 shares, compared to its average volume of 19,026,078. Recursion Pharmaceuticals, Inc. has a 12 month low of $2.77 and a 12 month high of $7.18. The stock has a 50 day moving average of $3.50 and a 200 day moving average of $3.37. The company has a market capitalization of $2.29 billion, a PE ratio of -4.11 and a beta of 1.04. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.The business had revenue of $7.67 million for the quarter, compared to analyst estimates of $10.97 million. During the same period in the prior year, the business earned ($0.41) EPS. Analysts predict that Recursion Pharmaceuticals, Inc. will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Ascent Wealth Partners LLC grew its holdings in Recursion Pharmaceuticals by 11.8% during the first quarter. Ascent Wealth Partners LLC now owns 28,081 shares of the company's stock worth $86,000 after purchasing an additional 2,974 shares during the period. Cherry Creek Investment Advisors Inc. lifted its holdings in Recursion Pharmaceuticals by 5.8% during the 1st quarter. Cherry Creek Investment Advisors Inc. now owns 70,536 shares of the company's stock valued at $217,000 after purchasing an additional 3,859 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in Recursion Pharmaceuticals by 33.2% during the first quarter. PNC Financial Services Group Inc. now owns 16,832 shares of the company's stock worth $52,000 after purchasing an additional 4,199 shares during the period. Sequoia Financial Advisors LLC boosted its position in Recursion Pharmaceuticals by 51.5% during the first quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company's stock worth $47,000 after purchasing an additional 5,156 shares during the period. Finally, Axxcess Wealth Management LLC increased its holdings in shares of Recursion Pharmaceuticals by 16.6% in the first quarter. Axxcess Wealth Management LLC now owns 37,516 shares of the company's stock valued at $115,000 after purchasing an additional 5,338 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Wall Street Zen raised shares of Recursion Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 29th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Finally, Morgan Stanley set a $5.30 price target on Recursion Pharmaceuticals in a report on Monday, August 17th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $8.06.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company's technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.